Replimune Group, Inc. (NASDAQ:REPL) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been given a consensus recommendation of “Moderate Buy” by the ten analysts that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $12.00.

A number of analysts have weighed in on the stock. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and raised their price target for the company from $11.00 to $17.00 in a research report on Tuesday, August 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a report on Monday, October 5th. Finally, JPMorgan Chase & Co. boosted their target price on Replimune Group from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th.

Insider Buying and Selling

In other Replimune Group news, CAO Andrew Schwendenman sold 7,632 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the completion of the sale, the chief accounting officer owned 99,425 shares of the company’s stock, valued at approximately $1,289,542.25. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the completion of the sale, the chief executive officer directly owned 708,151 shares of the company’s stock, valued at $9,184,718.47. This represents a 5.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 79,124 shares of company stock valued at $1,038,364 in the last 90 days. 5.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds have recently modified their holdings of REPL. Quantinno Capital Management LP raised its holdings in Replimune Group by 782.7% during the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock valued at $830,000 after acquiring an additional 96,188 shares during the period. Montanova Capital LLC boosted its stake in shares of Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after acquiring an additional 168,000 shares during the period. Seven Fleet Capital Management LP purchased a new stake in shares of Replimune Group during the first quarter worth about $921,000. Squarepoint Ops LLC purchased a new stake in shares of Replimune Group during the second quarter worth about $1,454,000. Finally, Deutsche Bank AG bought a new stake in Replimune Group during the 2nd quarter valued at approximately $857,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Trading Down 7.6%

NASDAQ REPL opened at $10.86 on Tuesday. Replimune Group has a 12 month low of $1.50 and a 12 month high of $16.33. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. The stock’s fifty day moving average price is $13.83 and its 200-day moving average price is $9.74. The stock has a market cap of $1.02 billion, a P/E ratio of -3.45 and a beta of 0.93.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). As a group, equities analysts forecast that Replimune Group will post -2.82 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company’s approach uses genetically engineered viruses designed to selectively replicate in tumors, directly destroy cancer cells and stimulate a broader immune response against malignant tissue.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 intended for use in patients with advanced solid tumors.